RxDoctor Payments Data

Maneka Kaul, MD

Family Medicine · Munster, INNPI 1174522148

Payments from drug & device makers

$876in general payments, 2019–2025

Across 22 payments — averaging $39.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$295
  • Inspire Medical Systems, Inc.$263
  • Eisai Inc.$95
  • AstraZeneca$80
  • Sanofi-aventis U.S. LLC$38
  • Pfizer$25
  • plus $82 from 4 others

What the payments were for

  • Food & beverage$876100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$876 in reported general payments places this provider in the 55th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$117,953
Medicare patients
319
Services billed
1,129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$109,614
JardianceEmpagliflozin38$44,981
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$39,796
EliquisApixaban28$25,992
Tresiba Flextouch U-100Insulin Degludec20$12,709
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$9,485
Breo ElliptaFluticasone/Vilanterol13$9,150
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$8,093
SynthroidLevothyroxine Sodium70$5,114
Arnuity ElliptaFluticasone Furoate14$4,037
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$3,786
Atorvastatin Calcium490$3,566
Fluticasone Propionate HfaFluticasone Propionate12$3,545
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,394
Ezetimibe68$3,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$24$62,46897 claims
Boehringer IngelheimJardiance$17$44,98138 claims
PfizerEliquis$25$25,99228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Munster

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →